A team of Italian researchers have injected autologous [the patient’s own] mesenchymal stem cells [MSCs] into patients suffering from digital ulcers (DU). The ulcers are brought about by systemic sclerosis (SSc), a connective tissue disease that progressively degrades blood vessels, causing havoc across multiple organ systems. DUs are slow to heal and are often unresponsive to therapies in individuals with SSc.
The researchers believe the implanted MSCs produced a series of proliferative growth factors to facilitate blood vessel, endothelial, fibroblast formation in all study patients, which led to both significant pain reduction and increased healing within 2-7 weeks post transplantation. "DU healing and significant improvement in DU-related pain in all of the patients in the study can certainly be regarded as extremely positive," said study co-author Dr. Nicoletta Del Papa of the U.O.C. Day Hospital Reumatolgia in Milan, Italy.
Treatments that promote improvement or healing in ischemic, SSc-related, treatment-resistant ulcers could lead to the development of novel therapeutic approaches for a broad range of medical conditions. We believe the best stem cells to use in emerging regenerative treatments will be the patient’s own stem cells as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783-6728 (877-StemSave) today.
To view the full article, click here.
The Future of Regenerative Medicine is Now™.